Fresenius SE & Co. KGaA

Earnings Release • Feb 23, 2011

News Details

Ad-hoc | 23 February 2011 07:05

Fresenius SE & Co. KGaA: Record results in 2010: All financial targets met or exceeded –

Fresenius SE & Co. KGaA / Key word(s): Final Results

23.02.2011 07:05

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Record results in 2010: All financial targets met or exceeded -
Positive outlook for 2011

Group sales increased by 13% at actual rates and by 8% in constant currency
to EUR15,972 million (2009: EUR14,164 million). Organic sales growth was
7%. Acquisitions contributed a further 1%. Currency translation had a
positive effect of 5%.

Group EBIT increased by 18% at actual rates and by 13% in constant currency
to EUR2,418 million (2009: EUR2,054 million). The EBIT margin increased to
15.1% (2009: 14.5%). All business segments achieved double-digit earnings
growth.

Group net income* increased by 28% at actual rates and by 23% in constant
currency to EUR660 million (2009: EUR514 million). Earnings per ordinary
share increased by 28% to EUR4.08.

Net income** (including special items) grew to EUR622 million or EUR3.85
per ordinary share.

Based on the excellent financial results the Management Board will propose
to the Supervisory Board a dividend increase of 15% to EUR 0.86 per
ordinary share (2009: EUR 0.75).

For 2011, Fresenius projects sales growth of ≥7 % in constant currency. Net
income* is expected to increase by 8% to 12% in constant currency. This
will result in a 2010/2011 compounded annual net income growth rate of 15%
to 17%.

The Group's US GAAP financial results as of December 31, 2010 and as of
December 31, 2009 include the effects of mark-to-market accounting of the
Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR)
related to the acquisition of APP Pharmaceuticals. Adjusted earnings
represent the Group's business operations in the reporting period.

*Net income attributable to Fresenius SE & Co. KGaA; adjusted for the
effects of mark-to-market accounting of the Mandatory Exchangeable Bonds
(MEB) and the Contingent Value Rights (CVR) related to the acquisition of
APP Pharmaceuticals. Both are non-cash items.
**Net income attributable to Fresenius SE & Co. KGaA

(Financial statements according to U.S. GAAP)

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management

Bad Homburg v.d.H., February 23, 2011

End of note

23.02.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Deutschland
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
Terminbörse EUREX

End of Announcement DGAP News-Service

---